Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oaktree Acquisition III Life SciencesOACC +0.37%15 Return-on-Tangible-Equity is 3.26% as of Jun. 2026, which is 14% below its 10-year median of 3.81. GuruFocus rates OACC with a GF Score™ of 15/100. Among 467 Diversified Financial Services companies, Oaktree Acquisition III Life Sciences ranks better than 77.3% on this metric.
The historical rank and industry rank for Oaktree Acquisition III Life Sciences's Return-on-Tangible-Equity or its related term are showing as below:
OACC'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.47 Med: 3.81 Max: 3.81
Current: 3.47
During the past 2 years, Oaktree Acquisition III Life Sciences's highest Return-on-Tangible-Equity was 3.81%. The lowest was 3.47%. And the median was 3.81%.
OACC's Return-on-Tangible-Equity is ranked better than 77.3% of 467
companies
in the Diversified Financial Services industry
Industry Median: 1.72
vs OACC: 3.47
Oaktree Acquisition III Life Sciences (NAS:OACC) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Oaktree Acquisition III Life Sciences Return-on-Tangible-Equity Related Terms
Oaktree Acquisition III Life Sciences Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oaktree Acquisition III Life Sciences Return-on-Tangible-Equity Chart
Oaktree Acquisition III Life Sciences Annual Data
Trend
Dec24
Dec25
Return-on-Tangible-Equity
0.00
3.81
Oaktree Acquisition III Life Sciences Quarterly Data
OACC vs DMAA, FACT, NTWO: Return-on-Tangible-Equity Comparison
For the Shell Companies subindustry, Oaktree Acquisition III Life Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oaktree Acquisition III Life Sciences Return-on-Tangible-Equity vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Oaktree Acquisition III Life Sciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Oaktree Acquisition III Life Sciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 3.26% mean?
Oaktree Acquisition III Life Sciences (OACC) has a Return-on-Tangible-Equity of 3.26% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Oaktree Acquisition III Life Sciences and its competitors. This is 14% below median its historical median of 3.81. Over the past decade, Oaktree Acquisition III Life Sciences' Return-on-Tangible-Equity has ranged from 3.47 to 3.81. According to the industry distribution chart, Oaktree Acquisition III Life Sciences ranks #106 out of 467 companies in the Diversified Financial Services industry, placing it in the top 22.7%.
Is Oaktree Acquisition III Life Sciences' Return-on-Tangible-Equity too high?
Oaktree Acquisition III Life Sciences' current Return-on-Tangible-Equity of 3.26% is 14% below median its 10-year median of 3.81. Over the past 10 years, this metric has ranged from a low of 3.47 to a high of 3.81. The Diversified Financial Services industry median Return-on-Tangible-Equity is 1.72. Oaktree Acquisition III Life Sciences' value of 3.26% is 89.5% above this industry median. Based on the distribution chart, Oaktree Acquisition III Life Sciences ranks #106 out of 467 companies in the Diversified Financial Services industry, which is in the top quartile — a strong position relative to peers. Overall, Oaktree Acquisition III Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Oaktree Acquisition III Life Sciences' Return-on-Tangible-Equity compare to DMAA and FACT?
According to the Diversified Financial Services industry distribution chart, Oaktree Acquisition III Life Sciences ranks #106 out of 467 companies for Return-on-Tangible-Equity. This places Oaktree Acquisition III Life Sciences in the top 23% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 1.72. Oaktree Acquisition III Life Sciences' value of 3.26% is 89.5% above this benchmark. Historically, Oaktree Acquisition III Life Sciences' own Return-on-Tangible-Equity has ranged from 3.47 to 3.81 over the past decade. While the company's 10-year median is 3.81 vs. the industry median of 1.72, Oaktree Acquisition III Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Diversified Financial Services company?
The median Return-on-Tangible-Equity among Diversified Financial Services companies is 1.72, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oaktree Acquisition III Life Sciences's current Return-on-Tangible-Equity of 3.26% is 89.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Oaktree Acquisition III Life Sciences and its competitors. For the Diversified Financial Services industry, the median Return-on-Tangible-Equity is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oaktree Acquisition III Life Sciences's current Return-on-Tangible-Equity is 3.26%, which is 14% below median its own 10-year median of 3.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oaktree Acquisition III Life Sciences stock overvalued right now?
Oaktree Acquisition III Life Sciences (OACC) has a current Return-on-Tangible-Equity of 3.26%. The current Return-on-Tangible-Equity is 3.26%, which is 14% below median its 10-year median of 3.81 and 89.5% above the Diversified Financial Services industry median of 1.72. Oaktree Acquisition III Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Oaktree Acquisition III Life Sciences (OACC), the current Return-on-Tangible-Equity is 3.26% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OACC has been successfully added to your 
